Industry: Biomedical Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A French biomedical company, headquartered in Paris, France, was established in 2012. Its core mission is to realize the promise of cancer immunotherapy, focusing on developing ready-made and innovative tumor treatment programs, targeting a wide range of tumor types. The company relies on its proprietary "immune imitation" technology platform to identify and develop functional molecules with therapeutic potential from human intestinal microbiota. The platform aims to stimulate effector memory T cells in patients, so as to generate a strong and lasting immune response and effectively overcome the immune tolerance against autoantigens.
Core technical services:
1. Functional analysis and target discovery of microbiome.
The active proteins produced by intestinal microorganisms were systematically screened by Qualcomm metagenomic sequencing and protein omics. Identify key molecules that can affect immune response, metabolic balance or inflammatory signaling pathway for drug development and biomarker determination.
2. Tumor immunotherapy platform
Using the "molecular mimicry" protein from microorganisms, human T cells can be activated to recognize and attack tumors, which can be used to develop various cancer vaccines and combined immunotherapy.
3. Biomarkers
Based on the characteristic map of microbiome, the markers used for disease early screening, curative effect monitoring and individualized treatment are identified.
Cooperation mode:
Seeking partners who need innovative immune and metabolic therapy solutions in biomedical diagnosis industry.